Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends

Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.

Please leave this field empty

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.